CombinatoRx has opted to abandon a development program for its rheumatoid arthritis therapy, CRx-150, after the latest set of trial data failed to demonstrate the kind of effectiveness needed to compete for that market. Researchers said that the therapy did demonstrate statistically significant responses for two key criteria in the trial, but failed to perform in a third.
"The level of activity observed with CRx-150 would not be competitive within the CombinatoRx product portfolio or the RA marketplace, as our lead RA product candidate, CRx-102, has demonstrated a much stronger clinical profile to date," Alexis Borisy, President and CEO of CombinatoRx. "We look forward to providing an update on the CombinatoRx pipeline including CRx-102, CRx-191 and CRx-401 among others at our R&D Day event in Cambridge on July 24th."
- check out the release
CombinatoRx gains $7M from extended research pact. Report
CombinatoRx reports failure in Phase II RA trial. Report
Phase II failure for CombinatoRx therapy. Report
CombinatoRx surges on positive Phase II data. Report